sellModerate cluster of 3
Kalia Kumud sold $205k of GH
Chief Information Officer at Guardant Health, Inc.. 7,000 shares at an average of $29.25, traded Nov 18, 2024, filed Nov 19, 2024.
Warning score
52Value
$205k
7,000 shares
Holdings after
17,744
-28% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001576280-24-000287, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 18, 2024 | SOpen-market sale Common Stock | -7,000 | $29.25 | $205k | 17,744 | Nov 19, 2024 |
Related signals
Other insiders at Guardant Health, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 26Weak | sell10b5-1 | GH Guardant Health, Inc. | Azar Alex M II director | $145k | 826 | |
| 3Weak | sell 210b5-1 | GH Guardant Health, Inc. | Tariq Musa director | $5,069 | 116 | |
| 31Weak | sell 3 | GH Guardant Health, Inc. | Kalia Kumud Chief Information Officer | $151k | 3,500 | |
| 0Weak | sell 310b5-1 | GH Guardant Health, Inc. | Joyce Meghan V. director | $4,271 | 100 | |
| 3Weak | sell 210b5-1 | GH Guardant Health, Inc. | Tariq Musa director | $5,606 | 116 | |
| 0Weak | sell10b5-1 | GH Guardant Health, Inc. | Tariq Musa director | $4,359 | 116 | |
| 0Weak | sell10b5-1 | GH Guardant Health, Inc. | Tariq Musa director | $4,043 | 116 | |
| 7Weak | sell 210b5-1 | GH Guardant Health, Inc. | Tariq Musa director | $81k | 2,320 | |
| 10Weak | sell 310b5-1 | GH Guardant Health, Inc. | Joyce Meghan V. director | $3,590 | 100 | |
| 38Weak | sell 3 | GH Guardant Health, Inc. | CLARK IAN T director | $245k | 8,318 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.